Cargando…

The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up

It is difficult to treat cardiorenal syndrome (CRS) in clinical practice, which is the common reason for the death of patients. This report aimed to describe the effects of sacubitril/valsartan treatment on cardiac and renal functions of a patient with cardiorenal syndrome type 4 (CRS4) after more t...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Shuiqin, Zhou, Tingting, Yu, Le, Chen, Yunmin, Zhang, Zhihong, Wang, Jinquan, Yu, Yusheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962615/
https://www.ncbi.nlm.nih.gov/pubmed/35360715
http://dx.doi.org/10.3389/fmed.2022.817833
_version_ 1784677839120891904
author Cheng, Shuiqin
Zhou, Tingting
Yu, Le
Chen, Yunmin
Zhang, Zhihong
Wang, Jinquan
Yu, Yusheng
author_facet Cheng, Shuiqin
Zhou, Tingting
Yu, Le
Chen, Yunmin
Zhang, Zhihong
Wang, Jinquan
Yu, Yusheng
author_sort Cheng, Shuiqin
collection PubMed
description It is difficult to treat cardiorenal syndrome (CRS) in clinical practice, which is the common reason for the death of patients. This report aimed to describe the effects of sacubitril/valsartan treatment on cardiac and renal functions of a patient with cardiorenal syndrome type 4 (CRS4) after more than 3 years of follow-up. A 77-year-old Chinese woman was admitted to our hospital because of CRS4 and stage 5 chronic kidney disease (CKD), who had a history of long-term proteinuria and renal failure. The patient's cardiothoracic ratio (CTR) measured by chest X–ray was 0.6. Cardiac ultrasonography showed that the left ventricular ejection fraction (LVEF) was 0.40. The patient had been treated for heart failure (HF) for 5 months, but there was no improvement in clinical manifestations, and the renal function gradually deteriorated. In our hospital, she received sacubitril/valsartan treatment for at least 40 months. The symptoms of HF relieved, and the indices of cardiac function improved. In addition, the patient's renal function was stable. During the treatment, the dosage of sacubitril/valsartan needed to be adjusted to achieve the optimal therapeutic effect. Follow-up results showed that she achieved cardiac function of New York Heart Association (NYHA) class II with an ejection fraction of 0.60 and E/A > 1 indicated by echocardiogram, and did not develop hyperkalemia. In summary, the improvement of cardiac and renal functions of the CRS4 patient was associated with the long-term sacubitril/valsartan treatment.
format Online
Article
Text
id pubmed-8962615
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89626152022-03-30 The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up Cheng, Shuiqin Zhou, Tingting Yu, Le Chen, Yunmin Zhang, Zhihong Wang, Jinquan Yu, Yusheng Front Med (Lausanne) Medicine It is difficult to treat cardiorenal syndrome (CRS) in clinical practice, which is the common reason for the death of patients. This report aimed to describe the effects of sacubitril/valsartan treatment on cardiac and renal functions of a patient with cardiorenal syndrome type 4 (CRS4) after more than 3 years of follow-up. A 77-year-old Chinese woman was admitted to our hospital because of CRS4 and stage 5 chronic kidney disease (CKD), who had a history of long-term proteinuria and renal failure. The patient's cardiothoracic ratio (CTR) measured by chest X–ray was 0.6. Cardiac ultrasonography showed that the left ventricular ejection fraction (LVEF) was 0.40. The patient had been treated for heart failure (HF) for 5 months, but there was no improvement in clinical manifestations, and the renal function gradually deteriorated. In our hospital, she received sacubitril/valsartan treatment for at least 40 months. The symptoms of HF relieved, and the indices of cardiac function improved. In addition, the patient's renal function was stable. During the treatment, the dosage of sacubitril/valsartan needed to be adjusted to achieve the optimal therapeutic effect. Follow-up results showed that she achieved cardiac function of New York Heart Association (NYHA) class II with an ejection fraction of 0.60 and E/A > 1 indicated by echocardiogram, and did not develop hyperkalemia. In summary, the improvement of cardiac and renal functions of the CRS4 patient was associated with the long-term sacubitril/valsartan treatment. Frontiers Media S.A. 2022-03-11 /pmc/articles/PMC8962615/ /pubmed/35360715 http://dx.doi.org/10.3389/fmed.2022.817833 Text en Copyright © 2022 Cheng, Zhou, Yu, Chen, Zhang, Wang and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Cheng, Shuiqin
Zhou, Tingting
Yu, Le
Chen, Yunmin
Zhang, Zhihong
Wang, Jinquan
Yu, Yusheng
The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up
title The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up
title_full The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up
title_fullStr The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up
title_full_unstemmed The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up
title_short The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up
title_sort effect of sacubitril/valsartan treatment on cardiac and renal functions of a patient with cardiorenal syndrome type 4 and stage 5 ckd after more than three years of follow-up
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962615/
https://www.ncbi.nlm.nih.gov/pubmed/35360715
http://dx.doi.org/10.3389/fmed.2022.817833
work_keys_str_mv AT chengshuiqin theeffectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup
AT zhoutingting theeffectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup
AT yule theeffectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup
AT chenyunmin theeffectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup
AT zhangzhihong theeffectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup
AT wangjinquan theeffectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup
AT yuyusheng theeffectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup
AT chengshuiqin effectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup
AT zhoutingting effectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup
AT yule effectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup
AT chenyunmin effectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup
AT zhangzhihong effectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup
AT wangjinquan effectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup
AT yuyusheng effectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup